Navigation Links
EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product
Date:5/1/2008

Strategic Transactions Increase EUSA's Focus on Late-Stage and Marketed

Products

DOYLESTOWN, Pennsylvania and OXFORD, England, May 1 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has divested its monoclonal antibody research business to the French company International Drug Development (IDD). Concurrently, EUSA has divested its recombinant L-asparaginase therapeutic research program for acute lymphoblastic leukemia to the Alize Pharma Group. EUSA acquired both the antibody business and oncology program as part of its 2007 acquisition of OPi SA.

"These two transactions further underline EUSA's ongoing success in divesting early-stage programs while retaining a clear strategic focus on late-stage and marketed products," said Bryan Morton, Chief Executive of EUSA Pharma. "As we continue to rapidly build our business around our commercial infrastructure in the US and Europe, we are creating the opportunity to compete effectively with major players as an attractive partner for companies seeking specialist transatlantic commercialization and late-stage development expertise in the oncology, pain control and critical care areas."

EUSA's antibody research business is based in Dardilly, France, and consists of a team of research and development scientists, laboratories and a library of approximately 600 murine antibodies, of which a high proportion are currently characterized. The fully human anti-interleukin-6 antibody, which EUSA recently out-licensed to GlaxoSmithKline, was the first therapeutic antibody to arise from this library. Other antibodies derived from the library target indications in oncology and inflammation.

The divestment agreement for EUSA's recombinant L-asparaginase therapeutic research program includes an option for the company to license back any resulting product.
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
(Date:10/22/2014)... Md. (PRWEB) October 21, 2014 Shimadzu ... an LC/MS/MS data tool for the pain management and ... of data processing and review by allowing users to ... to clinicians. , QuantAnalytics allows analysts to filter ... This expedites data processing by eliminating the need to ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
Breaking Biology Technology:The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... at the National Institute of Standards and Technology (NIST) ... viscosity measurementscritical data for a wide variety of fields ... as small as a few nanoliters. Currently a table-top ... tool for biotechnologists studying minute quantities of complex materials ...
... Mr. Robert Nealon reports: IGEN Networks Corp. ... Standard and Poor,s ("S&P") has approved IGEN for their ... Records is considered the premier source for information on ... professionals. As part of the approval, IGEN,s corporate profile ...
... of Services in Neuronal Research Using Human iPS... -- YOKOHAMA, Japan, September 1, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Micro rheometer is latest Lab On a Chip device 2IGEN Networks Corp. obtains Blue Sky Statutory Compliance in 38 States with Approval of Standard & Poor's 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... 3, 2010 Genes interact in complex networks that govern ... relationships. Researchers are now discovering how biological networks change ... today in Genome Research ( www.genome.org ), scientists ... light on how interactions go awry in disease. MicroRNAs ...
... Researchers from the University of Leeds, UK, the ... for Molecular Medicine (MDC) in Berlin, Germany, have ... Their studies have identified how ,junk, DNA promotes the ... Professor Constanze Bonifer (University of Leeds) and Dr Stephan ...
... oil could help prevent ulcerative colitis, according to a new ... Anglia (UEA). Presented today at the Digestive Disease ... with a diet rich in oleic acid which is ... ulcerative colitis. Oleic acid is a monounsaturated fatty acid found ...
Cached Biology News:MicroRNA network study implicates rewired interactions in cancer 2'Junk DNA' drives cancer growth 2Olive oil could guard against developing ulcerative colitis 2
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ...
Biology Products: